These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34273208)

  • 1. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial.
    Cowan RA; Scarisbrick JJ; Zinzani PL; Nicolay JP; Sokol L; Pinter-Brown L; Quaglino P; Iversen L; Dummer R; Musiek A; Foss F; Ito T; Rosen JP; Medley MC
    J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):2225-2238. PubMed ID: 34273208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome.
    Beylot-Barry M; Booken N; Weishaupt C; Scarisbrick J; Wu W; Rosen JP; Medley MC
    J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):311-316. PubMed ID: 35993803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
    Kim YH; Bagot M; Pinter-Brown L; Rook AH; Porcu P; Horwitz SM; Whittaker S; Tokura Y; Vermeer M; Zinzani PL; Sokol L; Morris S; Kim EJ; Ortiz-Romero PL; Eradat H; Scarisbrick J; Tsianakas A; Elmets C; Dalle S; Fisher DC; Halwani A; Poligone B; Greer J; Fierro MT; Khot A; Moskowitz AJ; Musiek A; Shustov A; Pro B; Geskin LJ; Dwyer K; Moriya J; Leoni M; Humphrey JS; Hudgens S; Grebennik DO; Tobinai K; Duvic M;
    Lancet Oncol; 2018 Sep; 19(9):1192-1204. PubMed ID: 30100375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
    Horwitz S; Zinzani PL; Bagot M; Kim YH; Moskowitz AJ; Porcu P; Dwyer K; Sun W; Herr FM; Scarisbrick J
    Leuk Lymphoma; 2021 Dec; 62(13):3109-3118. PubMed ID: 34304674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Grimm SE; Witlox W; Wolff R; Chalker A; Hiligsmann M; Wijnen B; Ahmadu C; Ryder S; Armstrong N; Duffy S; Syndikus I; Kleijnen J; Joore MA
    Pharmacoeconomics; 2022 May; 40(5):509-518. PubMed ID: 34664200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
    Blackmon AL; Pinter-Brown L
    Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.
    Porcu P; Hudgens S; Horwitz S; Quaglino P; Cowan R; Geskin L; Beylot-Barry M; Floden L; Bagot M; Tsianakas A; Moskowitz A; Huen A; Dreno B; Dalle S; Caballero D; Leoni M; Dale S; Herr F; Duvic M
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):97-105. PubMed ID: 33158772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
    Lewis DJ; Rook AH
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.
    Beylot-Barry M; Quereux G; Nardin C; Duval-Modeste AB; Dereure O; Dalac-Rat S; Dobos G; Pham-Ledard A; Ram-Wolff C; D'Incan M; Grange F; Braniste V; Bagot M
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1777-1784. PubMed ID: 37113040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.
    Kasamon YL; Chen H; de Claro RA; Nie L; Ye J; Blumenthal GM; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Dec; 25(24):7275-7280. PubMed ID: 31366601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: a subgroup analysis of the phase III MAVORIC trial.
    Johnson WT; Kartan S; Sokol K; Nikbakht N; Porcu P
    Leuk Lymphoma; 2021 Aug; 62(8):1877-1883. PubMed ID: 33618592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care.
    Hawkins N; Muszbek N; Evans R; McNamara L; Jones T
    J Comp Eff Res; 2023 Oct; 12(10):e230017. PubMed ID: 37642410
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome.
    Hawkins N; Muszbek N; Evans R; Dequen-O'Byrne P; Jones T; McNamara L
    J Comp Eff Res; 2022 Aug; 11(11):805-813. PubMed ID: 35678206
    [No Abstract]   [Full Text] [Related]  

  • 14. Health-related quality of life in cutaneous T-cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome.
    Ortiz Romero PL; Kim YH; Molloy K; Quaglino P; Scarisbrick J; Thornton S; Sandilands K; Dent JE; Nixon A; Williams A; Shinohara MM
    J Eur Acad Dermatol Venereol; 2024 Sep; ():. PubMed ID: 39315857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.
    Hirotsu KE; Neal TM; Khodadoust MS; Wang JY; Rieger KE; Strelo J; Hong E; Kim YH; Kwong BY
    JAMA Dermatol; 2021 Jun; 157(6):700-707. PubMed ID: 33881447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure-Response Analysis for Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma.
    Mukai M; Mould D; Maeda H; Narushima K; Greene D
    J Clin Pharmacol; 2020 Jan; 60(1):50-57. PubMed ID: 31840837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma.
    Watson S; Marx JB
    J Adv Pract Oncol; 2019; 10(8):883-888. PubMed ID: 33425472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.
    Scarisbrick JJ; Hodak E; Bagot M; Stranzenbach R; Stadler R; Ortiz-Romero PL; Papadavid E; Evison F; Knobler R; Quaglino P; Vermeer MH
    Eur J Cancer; 2018 Apr; 93():47-56. PubMed ID: 29477101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
    Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
    Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
    [No Abstract]   [Full Text] [Related]  

  • 20. Cutaneous T cell lymphoma treated with mogamulizumab monotherapy and mogamulizumab plus etoposide combined therapy: A real-world case series.
    Amagai R; Kambayashi Y; Ohuchi K; Furudate S; Hashimoto A; Asano Y; Fujimura T
    Dermatol Ther; 2022 Nov; 35(11):e15858. PubMed ID: 36161437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.